However, two particular points that need to be explained: One, for CAFs, depletion of YAP has more obvious influence than the depletion of TAZ (17), indicating that the downstream component of the signaling pathway which mediated by YAP is not only TAZ; Two, in breast cancer, not only the activity of MST1/2 doesn’t weaken in CAFs, but also the activity of LATS kinases and phosphorylated YAP increases (17), indicating that activation mode of YAP in CAF is different from the typical model. The gene discussed is YAP1; the disease is breast cancer.